{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:31:04Z","timestamp":1791873064003,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Obesity"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Individuals with obesity have a heightened risk of developing serious comorbidities, and pharmacological treatments for people with obesity are limited. This phase 2 study assessed the safety and efficacy of JNJ\u201064565111, a dual agonist of glucagon\u2010like peptide\u20101 and glucagon receptors, in individuals with class II\/III obesity without type 2 diabetes. In this randomized, double\u2010blind, placebo\u2010controlled and open\u2010label active\u2010controlled, parallel\u2010group, multicentre study, participants aged 18 to 70\u2009years with a body mass index of 35 to 50\u2009kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    and stable weight were randomly assigned in a 1:1:2:2:2 ratio to blinded treatment with placebo; JNJ\u201064565111 (5.0, 7.4 or 10.0 mg, each with no dose escalation), or open\u2010label liraglutide 3.0 mg. The primary efficacy endpoint was percent change from baseline in body weight at week 26. Four\u2010hundred seventy four participants were randomized and 343 (72.4%) completed treatment. At week 26, placebo\u2010subtracted body weight changes (adjusted for multiplicity) were \u22126.8%, \u22128.1% and \u221210.0% for the JNJ\u201064565111 5.0 mg, 7.4 mg and 10.0 mg groups, respectively, and \u22125.8% for the liraglutide group. Incidence of treatment\u2010emergent adverse events, especially nausea and vomiting, was higher in each JNJ\u201064565111 treatment group compared to placebo and liraglutide. JNJ\u201064565111 significantly reduced body weight in a dose\u2010dependent manner vs placebo but was associated with greater incidence of treatment\u2010emergent adverse events.\n                  <\/jats:p>","DOI":"10.1111\/cob.12432","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T13:52:28Z","timestamp":1611237148000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Efficacy and safety of glucagon\u2010like peptide\u20101\/glucagon receptor co\u2010agonist\n                    <scp>JNJ<\/scp>\n                    \u201064565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose\u2010ranging study"],"prefix":"10.1111","volume":"11","author":[{"given":"Maria","family":"Alba","sequence":"first","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Yee","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Frustaci","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Spring House Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh N.","family":"Samtani","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3597-975X","authenticated-orcid":false,"given":"Penny","family":"Fleck","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC  Raritan New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.03.107"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12551"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000145546.97738.1E"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd14.160438"},{"key":"e_1_2_9_6_1","first-page":"S64","article-title":"Practical perspectives on the management of overweight and obesity","volume":"20","author":"Gregory RS","year":"2014","journal-title":"Am J Manag Care"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1098-3597(09)80005-7"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2015.10.031"},{"key":"e_1_2_9_9_1","volume-title":"The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults","author":"National Institutes of Health, National Heart, Lung, and Blood Institute, and North American Association for the Study of Obesity","year":"2000"},{"issue":"3","key":"e_1_2_9_10_1","first-page":"245","article-title":"Obesity drug therapy","volume":"38","author":"Baretic M","year":"2013","journal-title":"Minerva Endocrinol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281361"},{"key":"e_1_2_9_12_1","unstructured":"XENICAL (orlistat) capsules for oral use [package insert].South San Francisco CA:Genentech USA Inc;2015."},{"key":"e_1_2_9_13_1","unstructured":"BELVIQ\u00ae (lorcaserin hydrochloride) tablets for oral use [package insert].Woodcliff Lake NJ:Eisai Inc;2012."},{"key":"e_1_2_9_14_1","unstructured":"CONTRAVE\u00ae (naltrexone HCl and bupropion HCl) extended\u2010release tablets [package insert].Deerfield IL:Takeda Pharmaceuticals America Inc;2014."},{"key":"e_1_2_9_15_1","unstructured":"SAXENDA\u00ae (liraglutide [rDNA origin] injection) solution for subcutaneous use [package insert].Plainsboro NJ:Novo Nordisk Inc;2016."},{"key":"e_1_2_9_16_1","unstructured":"ADIPEX\u2010P\u00ae (phentermine hydrochloride USP) CIV for oral use [package insert].Sellersville PA:Teva Pharmaceuticals USA;2012."},{"key":"e_1_2_9_17_1","unstructured":"QSYMIA\u00ae (phentermine and topiramate extended\u2010release) capsules for oral use CIV [package insert].Mountain View CA:VIVUS Inc;2014."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802475"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/672658"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2016.08.005"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-0242"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12585"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0797"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.209"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3180caa3e3"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12971"},{"key":"e_1_2_9_27_1","volume-title":"Obesity and Dyslipidemia","author":"Feingold KR","year":"2015"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1998.tb00685.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2001.117510"}],"container-title":["Clinical Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cob.12432","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cob.12432","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cob.12432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T13:59:53Z","timestamp":1693663193000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cob.12432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/cob.12432"],"URL":"https:\/\/doi.org\/10.1111\/cob.12432","archive":["Portico"],"relation":{},"ISSN":["1758-8103","1758-8111"],"issn-type":[{"value":"1758-8103","type":"print"},{"value":"1758-8111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"2020-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12432"}}